Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia

Head and Neck

Volumn 34, Issue 12, 2012, Pages 1681-1703

  Adelstein, David J ^a   Ridge, John A ^b   Brizel, David M ^c   Holsinger, F Christopher ^d   Haughey, Bruce H ^e   O'Sullivan, Brian ^f   Genden, Eric M ^g   Beitler, Jonathan J ^h   Weinstein, Gregory S ⁱ   Quon, Harry ^j   Chepeha, Douglas B ^k   Ferris, Robert L ^l   Weber, Randal S ^d   Movsas, Benjamin ^m   Waldron, John ^f   Lowe, Val ⁿ   Ramsey, Scott ^o   Manola, Judith ^p   Yueh, Bevan ^q   Carey, Thomas E ^k   Bekelman, Justin E ⁱ   Konski, Andre A ^r   Moore, Eric ⁿ   Forastiere, Arlene ^j   Schuller, David E ^s   Lynn, Jean ^t   Ullmann, Claudio Dansky ^t   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Washington University in St Louis School of Medicine   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m HENRY FORD HOSPITAL   (United States)

ⁿ MAYO CLINIC   (United States)

^o Fred Hutchinson Cancer Research Center   (United States)

^p DANA FARBER CANCER INSTITUTE   (United States)

^q UNIVERSITY OF MINNESOTA   (United States)

^r WAYNE STATE UNIVERSITY   (United States)

^s OHIO STATE UNIVERSITY   (United States)

^t NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN;

CANCER SURGERY; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; HEAD AND NECK CARCINOMA; HEALTH CARE COST; HUMAN; LASER SURGERY; LYMPH NODE METASTASIS; MICROSURGERY; MUCOSA INFLAMMATION; NEPHROTOXICITY; OROPHARYNX CANCER; OTOTOXICITY; PAPILLOMAVIRUS INFECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; QUALITY OF LIFE; RADIATION DOSE; ROBOTICS; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSORAL CANCER RESECTION; TREATMENT OUTCOME;

EID: 84869507343     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23136     Document Type: Conference Paper

References (120)

1. Pignon JP, le Maitre A, Maillard E, Bourhis J,. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
2. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
3. Bentzen SM, Trotti A,. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007; 25: 4096-4103.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
5. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck 2009; 31: 1393-1422.
6. Grant DG, Salassa JR, Hinni ML, Pearson BW, Perry WC,. Carcinoma of the tongue base treated by transoral laser microsurgery, part one: untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006; 116: 2150-2155.
7. Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins D, Haughey BH,. Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 2009; 119: 1709-1719.
8. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011; 33: 1683-1694.
9. O'Malley BW Jr, Weinstein GS, Snyder W, Hockstein NG,. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006; 116: 1465-1472.
10. Weinstein GS, O'Malley BW Jr, Snyder W, Sherman E, Quon H,. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133: 1220-1226.
11. Genden EM, Desai S, Sung CK,. Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head Neck 2009; 31: 283-289.
12. Moore EJ, Olsen KD, Kasperbauer JL,. Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope 2009; 119: 2156-2164.
13. Iseli TA, Kulbersh BD, Iseli CE, Carroll WR, Rosenthal EL, Magnuson JS,. Functional outcomes after transoral robotic surgery for head and neck cancer. Otolaryngol Head Neck Surg 2009; 141: 166-171.
14. Salassa JR, Hinni ML, Grant DG, Hayden RE,. Postoperative bleeding in transoral laser microsurgery for upper aerodigestive tract tumors. Otolaryngol Head Neck Surg 2008; 139: 453-459.
15. Holsinger FC, McWhorter AJ, Menard M, Garcia D, Laccourreye O,. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: I. Technique, complications, and functional results. Arch Otolaryngol Head Neck Surg 2005; 131: 583-591.
16. White HN, Moore EJ, Rosenthal EL, et al. Transoral robotic-assisted surgery for head and neck squamous cell carcinoma: one- and 2-year survival analysis. Arch Otolaryngol Head Neck Surg 2010; 136: 1248-1252.
17. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854.
18. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
19. Dobrowsky W, Naude J,. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000; 57: 119-124.
20. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804.
21. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-1324.
22. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
23. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
24. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
25. Holsinger FC,. Swing of the pendulum: optimizing functional outcomes in larynx cancer. Curr Oncol Rep 2008; 10: 170-175.
26. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
27. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
28. Cadiere GB, Himpens J, Germay O, et al. Feasibility of robotic laparoscopic surgery: 146 cases. World J Surg 2001; 25: 1467-1477.
29. Desai SC, Sung CK, Jang DW, Genden EM,. Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract. Laryngoscope 2008; 118: 2187-2189.
30. 2 laser supraglottic laryngectomy: experimental and clinical data. Laryngoscope 2007; 117: 817-820.
31. McLeod IK, Melder PC,. Da Vinci robot-assisted excision of a vallecular cyst: a case report. Ear Nose Throat J 2005; 84: 170-172.
32. Hockstein NG, Nolan JP, O'Malley BW Jr, Woo YJ,. Robotic microlaryngeal surgery: a technical feasibility study using the daVinci surgical robot and an airway mannequin. Laryngoscope 2005; 115: 780-785.
33. Hockstein NG, Nolan JP, O'Malley BW Jr, Woo YJ,. Robot-assisted pharyngeal and laryngeal microsurgery: results of robotic cadaver dissections. Laryngoscope 2005; 115: 1003-1008.
34. Weinstein GS, Magnuson JS, Moore EJ, et al. Transoral robotic surgery: interim analysis from a multicenter trial. Las Vegas, NV: American Head and Neck Society; 2010. Abstract #S002.
35. Garden AS, Kies MS, Weber RS,. To TORS or not to TORS: but is that the question? Arch Otolaryngol Head Neck Surg 2010; 136: 1085-1087.
36. Ridge JA,. We show pictures, they show curves. Arch Otolaryngol Head Neck Surg 2010; 136: 1170-1175.
37. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M,. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2003; 129: 36-43.
38. Lewis JS Jr, Carpenter DH, Thorstad WL, Zhang Q, Haughey BH,. Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol 2011; 24: 1413-1420.
39. Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH,. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012; 118: 3519-3530.
40. Fletcher GH,. Elective irradiation of subclinical disease in cancers of the head and neck. Cancer 1972; 29: 1450-1454.
41. Sanguineti G, Califano J, Stafford E, et al. Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 1356-1364.
42. Coskun HH, Ferlito A, Medina JE, et al. Retropharyngeal lymph node metastases in head and neck malignancies. Head Neck 2011; 33: 1520-1529.
43. Dirix P, Nuyts S, Bussels B, Hermans R, Van den Bogaert W,. Prognostic influence of retropharyngeal lymph node metastasis in squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 2006; 65: 739-744.
44. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004; 59: 28-42.
45. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010; 76: 1333-1338.
46. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60: 1425-1439.
47. Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 1356-1365.
48. O'Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 2001; 51: 332-343.
49. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011; 33: 1675-1682.
50. Morris L, Goenka A, Rao S, et al. Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer. Int J Radiat Oncol Biol Phys 2011; 81 (Suppl 2): S16 (abstract).
51. Murer K, Huber GF, Haile SR, Stoeckli SJ,. Comparison of morbidity between sentinel node biopsy and elective neck dissection for treatment of the N0 neck in patients with oral squamous cell carcinoma. Head Neck 2011; 33: 1260-1264.
52. Bentzen SM, Saunders MI, Dische S, Bond SJ,. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001; 60: 123-135.
53. Lindberg R,. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972; 29: 1446-1449.
54. Mukherji SK, Armao D, Joshi VM,. Cervical nodal metastases in squamous cell carcinoma of the head and neck: what to expect. Head Neck 2001; 23: 995-1005.
55. Byers RM, Wolf PF, Ballantyne AJ,. Rationale for elective modified neck dissection. Head Neck Surg 1988; 10: 160-167.
56. Bussels B, Hermans R, Reijnders A, Dirix P, Nuyts S, Van den Bogaert W,. Retropharyngeal nodes in squamous cell carcinoma of oropharynx: incidence, localization, and implications for target volume. Int J Radiat Oncol Biol Phys 2006; 65: 733-738.
57. Shimizu K, Inoue H, Saitoh M, et al. Distribution and impact of lymph node metastases in oropharyngeal cancer. Acta Otolaryngol 2006; 126: 872-877.
58. Coskun HH, Ferlito A, Medina JE, et al. Retropharyngeal lymph node metastases in head and neck malignancies. Head Neck 2011; 33: 1520-1529.
59. Vikram B, Strong EW, Shah JP, Spiro R,. Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984; 6: 724-729.
60. Amdur RJ, Parsons JT, Mendenhall WM, et al. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys 1989; 16: 25-36.
61. Richard JM, Sancho-Garnier H, Micheau C, et al. Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1,713 cases during a 15-year period. Laryngoscope 1987; 97: 97-101.
62. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
63. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
64. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843-850.
65. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993; 26: 3-11.
66. Genden EM, Kotz T, Tong CC, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011; 121: 1668-1674.
67. Hurtuk AM, Marcinow A, Agrawal A, et al. Quality-of-life outcomes in transoral robotic surgery. Otolaryngol Head Neck Surg 2012; 146: 68-73.
68. Leonhardt FD, Quon H, Abrahao M, et al. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck 2012; 34: 146-154.
69. Sinclair CF, McColloch NL, Carroll WR, et al. Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2011; 137: 1112-1116.
70. Rich JT, Liu J, Haughey BH,. Swallowing function after transoral laser microsurgery (TLM) ± adjuvant therapy for advanced-stage oropharyngeal cancer. Laryngoscope 2011; 121: 2381-2390.
71. Argiris A, Heron DE, Smith RP, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28: 5294-5300.
72. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999; 17: 1020-1028.
73. Maguire PD, Papagikos M, Hamann S, et al. Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1081-1088.
74. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, et al. A prospective study of quality of life in head and neck cancer patients. Part II: longitudinal data. Laryngoscope 2001; 111: 1440-1452.
75. Ringash J, Lockwood G, O'Sullivan B, et al. Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial. Radiother Oncol 2008; 87: 181-187.
76. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-2197.
77. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26: 3770-3776.
78. Langendijk JA, Doornaert P, Rietveld DH, et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009; 90: 189-195.
79. Caudell JJ, Schaner PE, Meredith RF, et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73: 410-415.
80. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle:a dose-effect relationship. Radiother Oncol 2007; 85: 64-73.
81. Guldiken Y, Orhan KS, Demirel T, et al. Assessment of shoulder impairment after functional neck dissection: long term results. Auris Nasus Larynx 2005; 32: 387-391.
82. Kuntz AL, Weymuller EA,. Impact of neck dissection on quality of life. Laryngoscope 1999; 109: 1334-1338.
83. Schiefke F, Akdemir M, Weber A, et al. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. Head Neck 2009; 31: 503-512.
84. Rogers SN, Scott B, Lowe D,. An evaluation of the shoulder domain of the University of Washington quality of life scale. Br J Oral Maxillofac Surg 2007; 45: 5-10.
85. Stuiver MM, van Wilgen CP, de Boer EM, et al. Impact of shoulder complaints after neck dissection on shoulder disability and quality of life. Otolaryngol Head Neck Surg 2008; 139: 32-39.
86. Chepeha DB, Taylor RJ, Chepeha JC, et al. Functional assessment using Constant's Shoulder Scale after modified radical and selective neck dissection. Head Neck 2002; 24: 432-436.
87. Salerno G, Cavaliere M, Foglia A, et al. The 11th nerve syndrome in functional neck dissection. Laryngoscope 2002; 112: 1299-1307.
88. Desai AS, Dramis A, Hearnden AJ,. Critical appraisal of subjective outcome measures used in the assessment of shoulder disability. Ann R Coll Surg Engl 2010; 92: 9-13.
89. Taylor RJ, Chepeha JC, Teknos TN, et al. Development and validation of the neck dissection impairment index: a quality of life measure. Arch Otolaryngol Head Neck Surg 2002; 128: 44-49.
90. van Wouwe M, de Bree R, Kuik DJ, et al. Shoulder morbidity after non-surgical treatment of the neck. Radiother Oncol 2009; 90: 196-201.
91. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
92. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
93. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
94. Caudell JJ, Schaner PE, Desmond RA, et al. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 76: 403-409.
95. Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg 1990; 116: 169-172.
96. Bernier J, Vermorken JB, Koch WM,. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 2006; 24: 2629-2635.
97. Fletcher GH, Lindberg RD, Jesse RH Jr,. The combination of radiation and surgery in oropharynx and laryngopharynx squamous cell carcinomas. Aktuelle Probl Chir 1970; 14: 347-366.
98. Cohen MA, Weinstein GS, O'Malley BW Jr, et al. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck 2011; 33: 573-580.
99. Quon H, O'Malley BW Jr, Weinstein GS,. Postoperative adjuvant therapy after transoral robotic resection for oropharyngeal carcinomas: rationale and current treatment approach. ORL J Otorhinolaryngol Relat Spec 2011; 73: 121-130.
100. Weinstein GS, O'Malley BW Jr, Hockstein NG,. Transoral robotic surgery: supraglottic laryngectomy in a canine model. Laryngoscope 2005; 115: 1315-1319.
101. Grant DG, Salassa JR, Hinni ML, et al. Carcinoma of the tongue base treated by transoral laser microsurgery, part two: persistent, recurrent and second primary tumors. Laryngoscope 2006; 116: 2156-2161.
102. Camp AA, Fundakowski C, Petruzzelli GJ, Emami B,. Functional and oncologic results following transoral laser microsurgical excision of base of tongue carcinoma. Otolaryngol Head Neck Surg 2009; 141: 66-69.
103. Petruzzelli GJ,. Transoral laser microsurgery: applications in head and neck oncology. Expert Rev Med Devices 2009; 6: 599-602.
104. Galati LT, Myers EN, Johnson JT,. Primary surgery as treatment for early squamous cell carcinoma of the tonsil. Head Neck 2000; 22: 294-296.
105. Walvekar RR, Li RJ, Gooding WE, et al. Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. Laryngoscope 2008; 118: 2129-2134.
106. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007; 8: 613-624.
107. Leslie A, Fyfe E, Guest P, et al. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a comparison of MRI and CT in T- and N-staging. J Comput Assist Tomogr 1999; 23: 43-49.
108. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP,. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008; 100: 712-720.
109. Trotta BM, Pease CS, Rasamny JJ, Raghavan P, Mukherjee S,. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics 2011; 31: 339-354.
110. Emonts P, Bourgeois P, Lemort M, Flamen P,. Functional imaging of head and neck cancers. Curr Opin Oncol 2009; 21: 212-217.
111. Brizel DM,. Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation. Cancer J 2011; 17: 159-165.
112. Roach MC, Turkington TG, Higgins KA, Hawk TC, Hoang JK, Brizel DM,. FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. Int J Radiat Oncol Biol Phys 2012; 82: 321-326.
113. Rose BS, Jeong J-H, Nath SK, et al. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011; 29: 3503-3509.
114. Lachin JM, Foulkes MA,. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986; 42: 507-519.
115. Dahlberg SE, Gray RJ, Johnson BE,. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol 2008; 26: 4233-4235.
116. Sanchez MM, Chen X,. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Statist Med 2006;25: 1169-1181.
117. Freidlin B, Korn EL, George SL, Gray R,. Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 2007; 25: 5019-5023.
118. Kleist P,. Composite endpoints: proceed with caution. Appl Clin Trials Online 2006. May be accessed at http://appliedclinicaltrialsonline.findpharma. com/appliedclinicaltrials/article/articleDetail.jsp?id=324331
119. Tomlinson G, Detsky AS,. Composite end points in randomized trials: there is no free lunch. JAMA 2010; 303: 267-268.
120. Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J,. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 2011; 104: 1848-1853.